The T helper cell activation method includes the T helper cell activation stage in which a WT1 peptide is added to the antigen cell, wherein the WT1 peptide has the ability to bind to the secondary MHC selected from HLA-DRB1 * 08:02, HLA-DRB1 * 13:02, One HLA-DRB1 * molecule 14:03, one HLA-DRB1 * molecule 14:05, one HLA-DQB1 * 03:02, one HLA-DQB1 * molecule 04:01. Claim 3: ingredients for the treatment or prevention of cancer, including WT1 type polynucleotide, which encodes WT1 type polynucleotide,an expression vector containing the polynucleotide or cells containing the expression vector, wherein the composition is administered to a subject having an MHC class II molecule selected from an HLA-DRB1 * 08: 02 molecule, an HLA-molecule. DRB1 * 13: 02, one HLA-DRB1 * 14: 03 molecule, one HLA-DRB1 * 14: 05 molecule, one HLA-DQB1 * 03: 02 molecule, and one HLA-DQB1 * 04: 01 molecule. Claim 7: Antigen-presenting cells exhibiting a complex of an antigenic peptide containing a WT1 peptide with an MHC class II molecule, wherein the MHC class II molecule is an MHC class II molecule selected from an HLA-DRB1 molecule. * 08: 02,one HLA-DRB1 * 13: 02 molecule, one HLA-DRB1 * 14: 03 molecule, one HLA-DRB1 * 14: 05 molecule, one HLA-DQB1 * 03: 02 molecule and one HLA-DQB1 * 04: 01 molecule. Claim 14: A pharmaceutical composition for treating or preventing cancer comprising, as an active ingredient, any of the antigen presenting cells according to any one of claims 7-9, the T helper cells according to any one of claims 10 - 12 or the cytotoxic T cells according to claim 13.Método para activar células T helper, que incluye la etapa de activación de células T helper por adición de un péptido WT1 a células que presentan antígeno, en donde el péptido WT1 tiene la capacidad de unirse con una molécula MHC de clase II seleccionada de molécula HLA-DRB1*08:02, una molécula HLA-DRB1*13:02, una molécula HLA-DRB1*14:03, una molécula HLA-DRB1*14:05, una molécula HLA-DQB1*03:02 y una molécula HL
